Cytokinetics Announces Data Relating to GSK-923295 and SB-743921 to Be Presented at the 2008 EORTC-NCI-AACR International Symposium
Three of these posters contain preclinical or clinical data relating to GSK-923295, currently being studied in a GlaxoSmithKline (GSK) sponsored Phase I clinical trial designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetic profile of this novel drug candidate in patients with solid tumors. In addition, a fourth poster contains preclinical and clinical data relating to SB-743921, currently being evaluated in a Cytokinetics sponsored Phase I/II clinical trial designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetic profile of this novel drug candidate administered as a one-hour infusion on days 1 and 15 of a 28-day schedule, and to assess the potential efficacy and the maximum tolerated dose of SB-743921 administered on this schedule in patients with Hodgkin or non-Hodgkin lymphoma.
Poster Presentations at EORTC-NCI-AACR Symposium:
The following posters relating to GSK-923295 are scheduled to be presented on Thursday, October 23, 2008 from 12:00-3:00 PM CEST in the Poster Hall:
Poster #397: "A Phase I Dose Escalation and Pharmacokinetic Study
of the Novel Mitotic Checkpoint Inhibitor GSK923295A in Patients
with Solid Tumors," Ronald Fleming, PhD, GlaxoSmithKline.
(Poster Session: Phase I)
Poster #342: "2-[18F] fluoro-2-deoxy-d-glucose Positron Emission
Tomography is an Early Biomarker for Tumor Growth Inhibition of
Human Colo205 Xenografts by the Novel and Selective CENP-E
Inhibitor, GSK923295A," David Sutton, PhD, GlaxoSmithKline.
(Poster Session: New Molecular Targets)
Poster #337: "GSK923295A, a Novel and Selective CENP-E Inhibitor,
Induces Pharmacodynamic Effects and Anti-tumor Activity in Human
Colo205 Xenografts," David Sutton, PhD, GlaxoSmithKline.
(Poster Session: New Molecular Targets)
The following poster relating to SB-743921 is scheduled to be presented on Thursday, October 23, 2008 from 12:00-3:00 PM CEST in the Poster Hall:
Poster #407: "Translational Development of the Novel Kinesin
Spindle Protein (KSP/Eg5) Inhibitor SB-743921 (SB-921) in Lymphoma:
From Preclinical Models to Phase 1 Studies," Jasmine Zain, MD,
Columbia University Medical Center, New York, New York.
(Poster Session: Phase I)
About Cytokinetics
Cytokinetics is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that may address areas of significant unmet clinical needs. Cytokinetics' cardiovascular disease program is focused to cardiac myosin, a motor protein essential to cardiac muscle contraction. Cytokinetics' lead compound from this program, CK-1827452, a novel small molecule cardiac myosin activator, entered Phase II clinical trials for the treatment of heart failure in 2007. Under a strategic alliance established in 2006, Cytokinetics and Amgen Inc. are performing joint research focused on identifying and characterizing activators of cardiac myosin as back-up and follow-on potential drug candidates to CK-1827452. Amgen has obtained an option for an exclusive license to develop and commercialize CK-1827452, subject to Cytokinetics' development and commercial participation rights. Cytokinetics' cancer program is focused on mitotic kinesins, a family of motor proteins essential to cell division. Under a strategic alliance established in 2001, Cytokinetics and GlaxoSmithKline (GSK) are conducting research and development activities focused on the potential treatment of cancer. Cytokinetics is developing two novel drug candidates that have arisen from this program, ispinesib and SB-743921, each a novel inhibitor of kinesin spindle protein (KSP), a mitotic kinesin. Cytokinetics is conducting a Phase I clinical trial of ispinesib as monotherapy as a first-line treatment in chemotherapy-naive patients with locally advanced or metastatic breast cancer. In addition, Cytokinetics is conducting a Phase I trial of SB-743921 in patients with non-Hodgkin or Hodgkin lymphoma. GSK has an option for the joint development and commercialization of ispinesib and SB-743921. Cytokinetics and GSK are conducting collaborative research activities directed to the mitotic kinesin centromere-associated protein E (CENP-E). GSK-923295, a CENP-E inhibitor, is being developed under the strategic alliance by GSK; GSK began a Phase I clinical trial with GSK-923295 in 2007. In April 2008, Cytokinetics announced the selection of a potential drug candidate directed towards skeletal muscle contractility which may be developed as a potential treatment for skeletal muscle weakness associated with neuromuscular diseases or other conditions. All of these drug candidates and potential drug candidates have arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the planned presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and the potential benefits of Cytokinetics' drug candidates and potential drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval, production and marketing of Cytokinetics' drug candidates and potential drug candidates that could slow or prevent clinical development, product approval or market acceptance, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results and that Cytokinetics' drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.
Contact:
Christopher S. Keenan
Director, Investor Relations
(650) 624-3000
SOURCE: Cytokinetics, Inc.